1. 21CFR320.1, 2015. Title 21: Food and Drugs: Part 320—Bioavailability and Bioequivalence Requirements, Subpart A—General Provisions. Available at http://www.ecfr.gov/cgi-bin/text-idx?SID=301bbb87cfab41036bc82f497f1aa9aa&node=pt21.5.320&rgn=div5#se21.5.320_121 (accessed 30.03.14.).
2. 21CFR320.24, 2015. Title 21: Food and Drugs: Part 320—Bioavailability and Bioequivalence Requirements, Subpart B—Procedures for Determining the Bioavailability or Bioequivalence of Drug Products. Available at http://www.ecfr.gov/cgi-bin/text-idx?SID=301bbb87cfab41036bc82f497f1aa9aa&node=pt21.5.320&rgn=div5#se21.5.320_124 (accessed 30.03.14.).
3. Chapter 58: antiviral agents (nonretroviral);Acosta,2011
4. Mechanism of corneal permeation of l-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea;Anand;Pharm. Res.,2002
5. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small;Bhandari;Arch. Orthop. Trauma Surg.,2002